Rochem International Inc Rochem International Inc

X

List of NDC API details of Candesartan Cilexetil Active Pharmaceutical Ingredient listed on PharmaCompass.com

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
751
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES

0

Flag India
Digital Content Digital Content
NA Not Available For Sales
Candesartan Cilexitel
POWDER (1kg/kg)
BULK INGREDIENT
55111-072
2010-03-30
2024-12-31
Flag India
Digital Content Digital Content
URL Supplier Web Content
CANDESARTAN CILEXETIL
POWDER (1kg/kg)
BULK INGREDIENT
72761-002
2019-02-09
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag India
Digital Content Digital Content
URL Supplier Web Content
CANDESARTAN CILEXETIL
POWDER (1kg/kg)
BULK INGREDIENT
52562-100
2012-08-08
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag India
Digital Content Digital Content
URL Supplier Web Content
Candesartan
POWDER (1kg/kg)
BULK INGREDIENT
68554-0038
1998-06-04
2023-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag India
Digital Content Digital Content
URL Supplier Web Content
candesartan cilexetil
POWDER (1kg/kg)
BULK INGREDIENT
65372-1128
2008-05-21
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag China
Digital Content Digital Content
URL Supplier Web Content
Candesartan Cilexetil
POWDER (1kg/kg)
BULK INGREDIENT
64220-114
2011-02-09
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
left grey arrow
right gray arrow
  • TABLET;ORAL - 16MG
  • TABLET;ORAL - 32MG
  • TABLET;ORAL - 4MG
  • TABLET;ORAL - 8MG
  • TABLET;ORAL - 16MG;12.5MG
  • TABLET;ORAL - 32MG;12.5MG
  • TABLET;ORAL - 32MG;25MG

Looking for 145040-37-5 / Candesartan Cilexetil API manufacturers, exporters & distributors?

Candesartan Cilexetil manufacturers, exporters & distributors 1

32

PharmaCompass offers a list of Candesartan Cilexetil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Candesartan Cilexetil manufacturer or Candesartan Cilexetil supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Candesartan Cilexetil manufacturer or Candesartan Cilexetil supplier.

PharmaCompass also assists you with knowing the Candesartan Cilexetil API Price utilized in the formulation of products. Candesartan Cilexetil API Price is not always fixed or binding as the Candesartan Cilexetil Price is obtained through a variety of data sources. The Candesartan Cilexetil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Candesartan Cilexetil

Synonyms

145040-37-5, Atacand, Tcv-116, Amias, Parapres, Kenzen

Cas Number

145040-37-5

Unique Ingredient Identifier (UNII)

R85M2X0D68

About Candesartan Cilexetil

Candesartan Cilexetil is a synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. After hydrolysis of candesartan cilexetil to candesartan during gastrointestinal absorption, candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.